News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

University of Texas MD Anderson Cancer Center Initiates Orders of IsoRay, Inc. (ISR)'s Cesium-131 for Intermediate Risk Prostate Cancer Study


10/10/2011 10:31:34 AM

RICHLAND, Wash.--(BUSINESS WIRE)--IsoRay Inc. (AMEX: ISR), a medical technology company and innovator in seed brachytherapy and medical radioisotope applications, announced today that MD Anderson Cancer Center has initiated orders of Cesium-131 brachytherapy (internal radiation therapy) seeds as it continues its clinical research study investigating brachytherapy's ability to help control intermediate risk prostate cancer. “Intermediate risk” is a classification of early stage prostate cancer that has shown a tendency to recur following standard treatments including surgery and radiation therapy.

Read at BioSpace.com

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES